Sarilumab is not Inferior to Tocilizumab in the Treatment of Cytokine Release Syndrome in COVID-19

Sarilumab is not Inferior to Tocilizumab in the Treatment of Cytokine Release Syndrome in COVID-19

Objective. Cytokine release syndrome (CRS) is a dangerous complication of the new coronavirus infection (COVID-19). The study aimed to compare sarilumab (SAR group) with tocilizumab (TOC group) and patients without anticytokine treatment (CON group) in treatment of CRS in COVID-19.Methods. The retro...

Full description

Saved in:
Bibliographic Details
Main Authors: V. T. Ivashkin, R. V. Maslennikov, E. V. Vasilieva, M. L. Chipurik, P. A. Semikova, V. V. Semenets, T. A. Russkova
Format: Article
Language:Russian
Published: Gastro LLC 2023-12-01
Series:Российский журнал гастроэнтерологии, гепатологии, колопроктологии
Subjects:
coronavirus
cytokine release syndrome
interleukin-6
tocilizumab
sarilumab
Online Access:https://www.gastro-j.ru/jour/article/view/676
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.gastro-j.ru/jour/article/view/676

Similar Items